Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Matched comparison of tisa-cel and axi-cel in R/R DLBCL

Emmanuel Bachy • 11 Jun 2022
EHA 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Tisagenlecleucel

Emmanuel Bachy, MD, PhD, Lyon Sud Hospital Center, Lyon, France, shares the results of a real-world study comparing the safety and efficacy of tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study found that patients treated with axi-cel had a prolonged progression-free survival (PFS) and overall survival (OS), but experienced higher rates of toxicity. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Emmanuel Bachy

0:44
Emerging options for patients with DLBCL who relapse after CAR-T therapy
Emmanuel Bachy • 11 Jun 2022
1:15
Emerging CAR-T therapies for T-cell lymphoma
Emmanuel Bachy • 11 Jun 2022
1:15
Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms
Emmanuel Bachy • 11 Jun 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals